Interim – Alligator Bioscience

2023-10-26

Regulatory

Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business update

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-04-25

Mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer completes enrolment following positive interim results; top-line data due Q1 2024 ...

2023-02-10

Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...

2022-10-20

Patient enrolment for OPTIMIZE-1 Phase 2 study ahead of schedule with top-line data now brought forward to Q1 2024 and interim data on track ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-04-27

Regulatory

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...

2022-02-112022-05-17

Regulatory

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...

2021-10-21

Regulatory

First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...